Tigertriever Distal Vessels Registry

Terminated

• Conditions: Ischemic Stroke
• Interventions: Device: Tigertriever

• Registration Number: NCT03871309
• Lead Sponsor: Rapid Medical

Brief Summary

A registry study to collect data on the Tigertriever device at restoring blood flow by removing clots in M2 or distal vessels in patients experiencing acute ischemic stroke, during commercial use.

Detailed Description

Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset.

Study Timeline

• Study First Submitted: 2019-02-21
• Study First Submitted QC: 2019-03-08
• Study First Posted: 2019-03-12
• Study Start: 2020-02-07
• Primary Completion: 2022-08-04
• Status Verified: 2022-10
• Study Completion: 2023-10-10
• Last Update Submitted: 2024-04-10
• Last Update Posted: 2024-04-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

• Patients who present with acute ischemic stroke, who can be treated within 6 hours of symptoms onset, who are either refractory to or ineligible for IV t-PA treatment and intend to be treated with thrombectomy.
• Patients ≥18
• NIHSS Score of ≥2
• Angiographically confirmed occlusion in a M2 or distal (medium to small) branch that is accessible to the Tigertriever device (17 or 13) as determined by the vessel diameter (≥1mm).
• Anticipated life expectancy of at least 6 months from presentation
• Signed informed consent form by the patient or a legally acceptable representative.

Exclusion Criteria

• Extended infarct - ischemic changes >1/3 MCA territory / 100 ml tissue or ASPECT score <5

  • Pre- stroke mRS ≥ 2

  • Unknown time of stroke symptom onset

  • Vessel diameter < 1mm

  • Angiographically evident extreme vessel tortuosity that may preclude the device from reaching the target area.

  • Occlusion/stenosis proximal to thrombus that precludes safe retrieval

  • Medical co-morbidities including but not limited to:

  • Uncontrolled coagulopathy such as International Normalized Ratio (INR) of > 3.0 or platelets count < 40 x109/L or APTT >50 sec

  • Serious concurrent medical illness: myocardial infarction, seizures, sepsis, uncontrolled diabetes, uncontrolled hypertension, brain tumor, renal impairment (eGFR <60).

  • Baseline glucose < 2.7 or > 22.2 mmol/L

  • Imaging features of:

    • raised intracranial pressure or significant mass effect (for example, midline shift, severe sulcal effacement, transcompartmental herniation)
    • intracranial hemorrhage
    • vascular malformation or aneurysm
    • significant vascular abnormality such as carotid dissection, complete carotid occlusion or large/medium vessel vasculitis

  • Allergy/sensitivity to nickel-titanium or contrast media

  • Females who are pregnant or lactating

  • Unable to obtain informed consent from the patient or a suitable legal representative

  • Any other contraindication to thrombectomy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Tigertriever	Tigertriever	Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.

Primary Outcome Measures

Name	Time	Method
Percentage of participants with Symptomatic Intracranial Hemorrhage (SICH) or new infarct within 24 (±12) hours post-procedure.	24 hours post procedure	Safety Endpoints. SICH shall be defined as Parenchymal Hematoma type 2 coupled with ≥4-point NIHSS deterioration at 24 hours.
Percentage of participants with a new occlusion.	Day 0 (end of procedure)	Safety Endpoints.
Percentage of participants with a TICI Score ≥IIb post procedure after first pass.	Day 0 (end of procedure)	Effectiveness Endpoints
Percentage of participants with a TICI Score ≥IIb post procedure.	Day 0 (end of procedure)	Effectiveness Endpoints

Trial Locations

Locations (1)

Imperial College Healthcare; 🇬🇧 London, United Kingdom